ArticleInflammatory intestinal diseases
Short- and Long-Term Effectiveness and Safety of Vedolizumab in Crohn's Disease: A Multicenter Retrospective Study from the Hokkaido Phoenix Cohort.
Article in Inflammatory intestinal diseases. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Real-world data on the long-term effectiveness of vedolizumab (VDZ) in East Asian patients with Crohn's disease (CD) remain limited. This study aimed to assess treatment persistence, clinical and endoscopic effectiveness, safety, and predictors of VDZ discontinuation in a multicenter Japanese cohort. Methods: A retrospective study was conducted across seven hospitals between June 2019 and October 2025, including patients with CD who initiated VDZ. Outcomes included VDZ continuation, factors associated with discontinuation, longitudinal changes in clinical and endoscopic indices, and adverse events. Results: Seventy-three patients were included. VDZ continuation was 62.3% and 37.8% at 1 and 3 years, respectively. In a multivariable Cox analysis, higher baseline C-reactive protein (CRP), higher body mass index (BMI), and female sex were independently associated with increased risk of VDZ discontinuation, with a trend toward better persistence among patients with ileal disease. In the 1-year analysis, female sex and prior biologic exposure predicted early discontinuation. CD activity index and its subscores improved during early treatment, and albumin levels increased gradually over time. Simple endoscopic score for CD improved at 1 and 2 years. Among patients with active disease, >40% achieved remission from week 6 onward. Adverse events occurred in 16.4%, with two (2.7%) patients discontinuing VDZ due to infusion reactions or psoriasiform rashes. Conclusion: VDZ demonstrated acceptable long-term durability, clinically meaningful and endoscopic improvement, and a favorable safety profile in Japanese real-world practice. Baseline CRP, BMI, and sex were important predictors of treatment persistence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.